MedTrace Logo

Glycine "Deficiency" and the Kinetics of Acylglycine in Morbid Obesity

NCT04658134 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-17

No results posted yet for this study

Summary

This study aims to evaluate the effects of oral glycine supplementation on plasma glycine concentration, intracellular glutathione (GSH) concentration, plasma acylglycine concentration, urine acylglycine concentration, and insulin resistance in subjects with morbid obesity.

This is an open-labelled trial. 20 adults with morbid obesity will be recruited. Following screening and baseline metabolic evaluations, eligible subjects will be given oral glycine supplements for 14 ± 5 days. Upon completing glycine supplementation, subjects will return for their post-supplement metabolic assessment.

The investigators hypothesize that oral glycine supplementation in morbidly obese patients normalizes plasma glycine concentration, increases intracellular GSH concentration, increases plasma and urinary acylglycine concentration, and improves insulin resistance.

Conditions

  • Morbid Obesity
  • Glycine; Metabolic Disorder

Interventions

DIETARY_SUPPLEMENT

Glycine

Oral glycine tablets (100 mg/kg/day) in divided doses

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • National University Health System, Singapore

    collaborator OTHER

  • Singapore General Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2021-12-15
Completion
2021-12-15

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04658134 on ClinicalTrials.gov